{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T21:57:10Z","timestamp":1790373430264,"version":"4.1.0"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T00:00:00Z","timestamp":1774051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005611","name":"University of Fukui","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005611","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin J Gastroenterol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Multicentric hepatocellular carcinoma (HCC) often exhibits a heterogeneous inter-nodal response to systemic therapy, leading to reduced therapeutic effectiveness. Here, we report the case of a 70-year-old woman with multicentric HCC treated with atezolizumab plus bevacizumab, followed by lenvatinib. While most nodules responded well to systemic therapy, one nodule at S7 exhibited progression. Distinct from the histology of another nodule that responded to atezolizumab plus bevacizumab, percutaneous ultrasound-guided biopsy of this progressive nodule revealed nuclear positivity for \u03b2-catenin. This finding suggested a potential role of \u03b2-catenin in immune checkpoint inhibitor resistance. Proton beam therapy was subsequently administered to the resistant lesion, achieving local control. The continuation of immune checkpoint therapy effectively maintained remission of the other nodules, and the patient remained in long-term remission without recurrence. This case indicates the importance of molecular profiling, including \u03b2-catenin expression, in cases of multicentric HCC to predict immune checkpoint inhibitor resistance and guide treatment strategies for each nodule. Additionally, it demonstrates the potential of proton beam therapy as a targeted therapeutic approach for immune checkpoint inhibitor-resistant nodules. These findings highlight the possible need for personalized treatment in multicentric HCC by integrating molecular and immunological insights to predict outcomes for complex tumor biology.<\/jats:p>","DOI":"10.1007\/s12328-025-02266-0","type":"journal-article","created":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T07:38:45Z","timestamp":1774078725000},"page":"601-607","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Successful treatment of \u03b2-catenin-positive, immune checkpoint inhibitor-resistant tumor in a case of multicentric hepatocellular carcinoma"],"prefix":"10.1007","volume":"19","author":[{"given":"Hirotaka","family":"Nomiya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidetaka","family":"Matsuda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuto","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Akazawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuto","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsushi","family":"Naito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Ohtani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiaki","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3160-3555","authenticated-orcid":false,"given":"Yasunari","family":"Nakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,21]]},"reference":[{"key":"2266_CR1","first-page":"209","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209\u201349.","journal-title":"CA Cancer J Clin"},{"key":"2266_CR2","doi-asserted-by":"publisher","first-page":"108","DOI":"10.1016\/j.ejca.2021.11.023","volume":"161","author":"H Rumgay","year":"2022","unstructured":"Rumgay H, Ferlay J, de Martel C, et al. Global, regional and national burden of primary liver cancer by subtype. Eur J Cancer. 2022;161:108\u201318.","journal-title":"Eur J Cancer"},{"key":"2266_CR3","doi-asserted-by":"publisher","first-page":"1749","DOI":"10.1001\/jamaoncol.2019.2996","volume":"5","author":"C Fitzmaurice","year":"2019","unstructured":"Fitzmaurice C, Abate D, Abbasi N, et al. Global, regional, and national cancer incidence, mortality, years of life lost, years lived with disability, and disability-adjusted life-years for 29 cancer groups, 1990 to 2017. JAMA Oncol. 2019;5:1749.","journal-title":"JAMA Oncol"},{"key":"2266_CR4","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"European Association for the Study of the Liver","year":"2018","unstructured":"European Association for the Study of the Liver. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69:182\u2013236.","journal-title":"J Hepatol"},{"key":"2266_CR5","doi-asserted-by":"publisher","first-page":"1516","DOI":"10.1002\/bjs.9263","volume":"100","author":"PT Kim","year":"2013","unstructured":"Kim PT, Jang JH, Atenafu EG, et al. Outcomes after hepatic resection and subsequent multimodal treatment of recurrence for multifocal hepatocellular carcinoma. Br J Surg. 2013;100:1516\u201322.","journal-title":"Br J Surg"},{"key":"2266_CR6","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1111\/hepr.13892","volume":"53","author":"K Hasegawa","year":"2023","unstructured":"Hasegawa K, Takemura N, Yamashita T, et al. Clinical practice guidelines for hepatocellular carcinoma: the Japan society of hepatology 2021 version (5th JSH-HCC Guidelines). Hepatol Res. 2023;53:383\u201390.","journal-title":"Hepatol Res"},{"key":"2266_CR7","doi-asserted-by":"publisher","first-page":"1922","DOI":"10.1097\/HEP.0000000000000466","volume":"78","author":"AG Singal","year":"2023","unstructured":"Singal AG, Llovet JM, Yarchoan M, et al. AASLD practice guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. Hepatology. 2023;78:1922\u201365.","journal-title":"Hepatology"},{"key":"2266_CR8","doi-asserted-by":"publisher","first-page":"2116","DOI":"10.1158\/1078-0432.CCR-18-2293","volume":"25","author":"JJ Harding","year":"2019","unstructured":"Harding JJ, Nandakumar S, Armenia J, et al. Prospective genotyping of hepatocellular carcinoma: clinical implications of next-generation sequencing for matching patients to targeted and immune therapies. Clin Cancer Res. 2019;25:2116\u201326.","journal-title":"Clin Cancer Res"},{"key":"2266_CR9","doi-asserted-by":"publisher","first-page":"380","DOI":"10.1159\/000516899","volume":"10","author":"M Morita","year":"2021","unstructured":"Morita M, Nishida N, Sakai K, et al. Immunological microenvironment predicts the survival of the patients with hepatocellular carcinoma treated with anti-PD-1 antibody. Liver Cancer. 2021;10:380\u201393.","journal-title":"Liver Cancer"},{"key":"2266_CR10","doi-asserted-by":"publisher","first-page":"1124","DOI":"10.1158\/2159-8290.CD-19-0074","volume":"9","author":"M Ruiz De Galarreta","year":"2019","unstructured":"Ruiz De Galarreta M, Bresnahan E, Molina-S\u00e1nchez P, et al. \u03b2-Catenin activation promotes immune escape and resistance to anti\u2013PD-1 therapy in hepatocellular carcinoma. Cancer Discov. 2019;9:1124\u201341.","journal-title":"Cancer Discov"},{"key":"2266_CR11","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1056\/NEJMoa1915745","volume":"382","author":"RS Finn","year":"2020","unstructured":"Finn RS, Qin S, Ikeda M, Galle PR, et al. Atezolizumab plus Bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382:1894\u2013905.","journal-title":"N Engl J Med"},{"key":"2266_CR12","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/S0928-4346(96)00325-8","volume":"6","author":"F Ichida","year":"1996","unstructured":"Ichida F, Tsuji T, Omata M, et al. New Inuyama classification; new criteria for histological assessment of chronic hepatitis. Int Hepatol Commun. 1996;6:112\u20139.","journal-title":"Int Hepatol Commun"},{"key":"2266_CR13","unstructured":"The Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 6, Rivised Version. Tokyo, Kanehara & Co., Ltd.; 2019 (in Japanese)."},{"key":"2266_CR14","doi-asserted-by":"publisher","first-page":"860","DOI":"10.1007\/s002689900318","volume":"21","author":"M Yasui","year":"1997","unstructured":"Yasui M, Harada A, Nonami T, et al. Potentially multicentric hepatocellular carcinoma: clinicopathologic characteristics and postoperative prognosis. World J Surg. 1997;21:860\u20135.","journal-title":"World J Surg"},{"key":"2266_CR15","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2009;45:228\u201347.","journal-title":"Eur J Cancer"},{"key":"2266_CR16","doi-asserted-by":"publisher","first-page":"2021","DOI":"10.1158\/1078-0432.CCR-18-3778","volume":"25","author":"R Pinyol","year":"2019","unstructured":"Pinyol R, Sia D, Llovet JM. Immune exclusion-Wnt\/CTNNB1 class predicts resistance to immunotherapies in HCC. Clin Cancer Res. 2019;25:2021\u20133.","journal-title":"Clin Cancer Res"},{"key":"2266_CR17","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1053\/j.gastro.2017.06.007","volume":"153","author":"D Sia","year":"2017","unstructured":"Sia D, Jiao Y, Martinez-Quetglas I, et al. Identification of an immune-specific class of hepatocellular carcinoma, based on molecular features. Gastroenterology. 2017;153:812\u201326.","journal-title":"Gastroenterology"},{"key":"2266_CR18","doi-asserted-by":"publisher","first-page":"615","DOI":"10.1159\/000518048","volume":"10","author":"T Aoki","year":"2021","unstructured":"Aoki T, Nishida N, Ueshima K, et al. Higher enhancement intrahepatic nodules on the hepatobiliary phase of Gd-EOB-DTPA-Enhanced MRI as a poor responsive marker of Anti-PD-1\/PD-L1 monotherapy for unresectable hepatocellular carcinoma. Liver Cancer. 2021;10:615\u201328.","journal-title":"Liver Cancer"},{"key":"2266_CR19","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1159\/000509554","volume":"9","author":"M Kudo","year":"2020","unstructured":"Kudo M. Gd-EOB-DTPA-MRI could predict WNT\/\u03b2-Catenin mutation and resistance to immune checkpoint inhibitor therapy in hepatocellular carcinoma. Liver Cancer. 2020;9:479\u201390.","journal-title":"Liver Cancer"},{"key":"2266_CR20","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1016\/j.jhep.2014.06.008","volume":"61","author":"A Ueno","year":"2014","unstructured":"Ueno A, Masugi Y, Yamazaki K, et al. OATP1B3 expression is strongly associated with Wnt\/\u03b2-catenin signalling and represents the transporter of gadoxetic acid in hepatocellular carcinoma. J Hepatol. 2014;61:1080\u20137.","journal-title":"J Hepatol"},{"key":"2266_CR21","doi-asserted-by":"publisher","first-page":"990","DOI":"10.1093\/annonc\/mdz103","volume":"30","author":"LX Xu","year":"2019","unstructured":"Xu LX, He MH, Dai ZH, et al. Genomic and transcriptional heterogeneity of multifocal hepatocellular carcinoma. Ann Oncol. 2019;30:990\u20137.","journal-title":"Ann Oncol"},{"key":"2266_CR22","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jhep.2019.12.014","volume":"72","author":"LQ Dong","year":"2020","unstructured":"Dong LQ, Peng LH, Ma LJ, et al. Heterogeneous immunogenomic features and distinct escape mechanisms in multifocal hepatocellular carcinoma. J Hepatol. 2020;72:896\u2013908.","journal-title":"J Hepatol"},{"key":"2266_CR23","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2020.102659","volume":"53","author":"M Fujita","year":"2020","unstructured":"Fujita M, Yamaguchi R, Hasegawa T, et al. Classification of primary liver cancer with immunosuppression mechanisms and correlation with genomic alterations. EBioMedicine. 2020;53:102659.","journal-title":"EBioMedicine"},{"key":"2266_CR24","doi-asserted-by":"publisher","first-page":"3053","DOI":"10.1002\/cncr.25809","volume":"117","author":"DA Bush","year":"2011","unstructured":"Bush DA, Kayali Z, Grove R, et al. The safety and efficacy of high-dose proton beam radiotherapy for hepatocellular carcinoma: a phase 2 prospective trial. Cancer. 2011;117:3053\u20139.","journal-title":"Cancer"},{"key":"2266_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.21037\/jgo.2019.04.02","volume":"11","author":"M Chuong","year":"2020","unstructured":"Chuong M, Kaiser A, Molitoris J, et al. Proton beam therapy for liver cancers. J Gastrointest Oncol. 2020;11:157\u201365.","journal-title":"J Gastrointest Oncol"},{"key":"2266_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/jpm12030436","volume":"12","author":"E Kotsifa","year":"2022","unstructured":"Kotsifa E, Vergadis C, Vailas M, et al. Transarterial chemoembolization for hepatocellular carcinoma: why, when, how? J Pers Med. 2022;12:436.","journal-title":"J Pers Med"}],"container-title":["Clinical Journal of Gastroenterology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12328-025-02266-0","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12328-025-02266-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T20:36:51Z","timestamp":1781642211000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12328-025-02266-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,21]]},"references-count":26,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["2266"],"URL":"https:\/\/doi.org\/10.1007\/s12328-025-02266-0","relation":{},"ISSN":["1865-7257","1865-7265"],"issn-type":[{"value":"1865-7257","type":"print"},{"value":"1865-7265","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,21]]},"assertion":[{"value":"28 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures followed were in accordance with the ethical standards of the committee responsible for human experimentation (institutional and national) and with the Helsinki Declaration of 1964 and its later amendments.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human or animal rights"}},{"value":"Informed consent was obtained from the patient included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}